Global Latent TB Detection Market

Latent TB Detection Comprehensive Study by End users (Hospitals, Diagnostic Centers, Laboratories, Others), Drug Type (First Line anti-TB Drugs, Second Line anti- TB Drugs), Test (TB skin test, TB blood tests) Players and Region - Global Market Outlook to 2030

Latent TB Detection Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Latent TB Detection
Tuberculosis (TB) is a contagious disorder brought on by using the micro organism Mycobacterium tuberculosis (MTB). Tuberculosis impacts the lungs in most cases, though it can additionally have an effect on different areas of the body. The majority of infections are asymptomatic, which is acknowledged as latent tuberculosis. About 10% of latent infections improve to lively illness, which kills about 1/2 of men and women who are contaminated if left untreated. A continual cough with blood-containing mucus, fever, night time sweats, and weight loss are all frequent signs of lively tuberculosis. Because of the weight loss, it used to be until now regarded as consuming. Other organ infections can generate a range of symptoms.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

QIAGEN (Germany), BioMeriux S.A. (France), F. Hoffmann La-Roche Ltd. (Switzerland), BD (United States), ARKRAY, Inc. (Japan), Abbott (United States), Serum Institute of India Pvt. Ltd (India), Oxford Immunotec Ltd (United Kingdom) and Lionex GmbH (Germany) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Latent TB Detection market by and Region.



On the basis of geography, the market of Latent TB Detection has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End users, the sub-segment i.e. Hospitals will boost the Latent TB Detection market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Type, the sub-segment i.e. First Line anti-TB Drugs will boost the Latent TB Detection market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Test, the sub-segment i.e. TB skin test will boost the Latent TB Detection market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Advancements Technology in Tuberculosis Diagnosis

Market Growth Drivers:
Growing Prevalence of Tuberculosis diseases

Challenges:
Limited Staff Capacity and Lack of Infrastructure Building in Health Systems Management

Restraints:
Shortage of Multidrug Resistant Tuberculosis

Opportunities:
Emerging Markets for TB diagnosis

Market Leaders and their expansionary development strategies
In January 2021, PerkinElmer, Waltham, Mass, has completed its previously announced acquisition of Oxford Immunotec Global, TB Diagnostics Specialist. the acquisition distinct clinical and logistical advantages of the test and see a great opportunity to leverage our automation capabilities and commercial channel access to bring tuberculosis testing to more customers around the world.”
In 2021, Abbott Launches New PediaSure in India – Latest Innovation to Support Catch-Up Growth and Unlock Growth Potential in Children. PediaSure, a complete and balanced nutrition solution with 37 growth nutrients, is scientifically tested to help improve immunity and bring visible growth to children in 90 days1.The new PediaSure is enhanced with arginine and natural vitamin K2, two important nutrients to help further support catch-up growth.


Key Target Audience
Manufactures, Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By End users
  • Hospitals
  • Diagnostic Centers
  • Laboratories
  • Others

By Drug Type
  • First Line anti-TB Drugs
  • Second Line anti- TB Drugs

By Test
  • TB skin test
  • TB blood tests

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Tuberculosis diseases
    • 3.3. Market Challenges
      • 3.3.1. Limited Staff Capacity
      • 3.3.2. Lack of Infrastructure Building in Health Systems Management
    • 3.4. Market Trends
      • 3.4.1. Advancements Technology in Tuberculosis Diagnosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Latent TB Detection, by End users, Drug Type, Test and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Latent TB Detection (Value)
      • 5.2.1. Global Latent TB Detection by: End users (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Diagnostic Centers
        • 5.2.1.3. Laboratories
        • 5.2.1.4. Others
      • 5.2.2. Global Latent TB Detection by: Drug Type (Value)
        • 5.2.2.1. First Line anti-TB Drugs
        • 5.2.2.2. Second Line anti- TB Drugs
      • 5.2.3. Global Latent TB Detection by: Test (Value)
        • 5.2.3.1. TB skin test
        • 5.2.3.2. TB blood tests
      • 5.2.4. Global Latent TB Detection Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Latent TB Detection (Price)
  • 6. Latent TB Detection: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. QIAGEN (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. BioMeriux S.A. (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann La-Roche Ltd. (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BD (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. ARKRAY, Inc. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abbott (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Serum Institute of India Pvt. Ltd (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Oxford Immunotec Ltd (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lionex GmbH (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Latent TB Detection Sale, by End users, Drug Type, Test and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Latent TB Detection (Value)
      • 7.2.1. Global Latent TB Detection by: End users (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Diagnostic Centers
        • 7.2.1.3. Laboratories
        • 7.2.1.4. Others
      • 7.2.2. Global Latent TB Detection by: Drug Type (Value)
        • 7.2.2.1. First Line anti-TB Drugs
        • 7.2.2.2. Second Line anti- TB Drugs
      • 7.2.3. Global Latent TB Detection by: Test (Value)
        • 7.2.3.1. TB skin test
        • 7.2.3.2. TB blood tests
      • 7.2.4. Global Latent TB Detection Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Latent TB Detection (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Latent TB Detection: by End users(USD Million)
  • Table 2. Latent TB Detection Hospitals , by Region USD Million (2018-2023)
  • Table 3. Latent TB Detection Diagnostic Centers , by Region USD Million (2018-2023)
  • Table 4. Latent TB Detection Laboratories , by Region USD Million (2018-2023)
  • Table 5. Latent TB Detection Others , by Region USD Million (2018-2023)
  • Table 6. Latent TB Detection: by Drug Type(USD Million)
  • Table 7. Latent TB Detection First Line anti-TB Drugs , by Region USD Million (2018-2023)
  • Table 8. Latent TB Detection Second Line anti- TB Drugs , by Region USD Million (2018-2023)
  • Table 9. Latent TB Detection: by Test(USD Million)
  • Table 10. Latent TB Detection TB skin test , by Region USD Million (2018-2023)
  • Table 11. Latent TB Detection TB blood tests , by Region USD Million (2018-2023)
  • Table 12. South America Latent TB Detection, by Country USD Million (2018-2023)
  • Table 13. South America Latent TB Detection, by End users USD Million (2018-2023)
  • Table 14. South America Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 15. South America Latent TB Detection, by Test USD Million (2018-2023)
  • Table 16. Brazil Latent TB Detection, by End users USD Million (2018-2023)
  • Table 17. Brazil Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 18. Brazil Latent TB Detection, by Test USD Million (2018-2023)
  • Table 19. Argentina Latent TB Detection, by End users USD Million (2018-2023)
  • Table 20. Argentina Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 21. Argentina Latent TB Detection, by Test USD Million (2018-2023)
  • Table 22. Rest of South America Latent TB Detection, by End users USD Million (2018-2023)
  • Table 23. Rest of South America Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 24. Rest of South America Latent TB Detection, by Test USD Million (2018-2023)
  • Table 25. Asia Pacific Latent TB Detection, by Country USD Million (2018-2023)
  • Table 26. Asia Pacific Latent TB Detection, by End users USD Million (2018-2023)
  • Table 27. Asia Pacific Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 28. Asia Pacific Latent TB Detection, by Test USD Million (2018-2023)
  • Table 29. China Latent TB Detection, by End users USD Million (2018-2023)
  • Table 30. China Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 31. China Latent TB Detection, by Test USD Million (2018-2023)
  • Table 32. Japan Latent TB Detection, by End users USD Million (2018-2023)
  • Table 33. Japan Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 34. Japan Latent TB Detection, by Test USD Million (2018-2023)
  • Table 35. India Latent TB Detection, by End users USD Million (2018-2023)
  • Table 36. India Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 37. India Latent TB Detection, by Test USD Million (2018-2023)
  • Table 38. South Korea Latent TB Detection, by End users USD Million (2018-2023)
  • Table 39. South Korea Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 40. South Korea Latent TB Detection, by Test USD Million (2018-2023)
  • Table 41. Taiwan Latent TB Detection, by End users USD Million (2018-2023)
  • Table 42. Taiwan Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 43. Taiwan Latent TB Detection, by Test USD Million (2018-2023)
  • Table 44. Australia Latent TB Detection, by End users USD Million (2018-2023)
  • Table 45. Australia Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 46. Australia Latent TB Detection, by Test USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Latent TB Detection, by End users USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Latent TB Detection, by Test USD Million (2018-2023)
  • Table 50. Europe Latent TB Detection, by Country USD Million (2018-2023)
  • Table 51. Europe Latent TB Detection, by End users USD Million (2018-2023)
  • Table 52. Europe Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 53. Europe Latent TB Detection, by Test USD Million (2018-2023)
  • Table 54. Germany Latent TB Detection, by End users USD Million (2018-2023)
  • Table 55. Germany Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 56. Germany Latent TB Detection, by Test USD Million (2018-2023)
  • Table 57. France Latent TB Detection, by End users USD Million (2018-2023)
  • Table 58. France Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 59. France Latent TB Detection, by Test USD Million (2018-2023)
  • Table 60. Italy Latent TB Detection, by End users USD Million (2018-2023)
  • Table 61. Italy Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 62. Italy Latent TB Detection, by Test USD Million (2018-2023)
  • Table 63. United Kingdom Latent TB Detection, by End users USD Million (2018-2023)
  • Table 64. United Kingdom Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 65. United Kingdom Latent TB Detection, by Test USD Million (2018-2023)
  • Table 66. Netherlands Latent TB Detection, by End users USD Million (2018-2023)
  • Table 67. Netherlands Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 68. Netherlands Latent TB Detection, by Test USD Million (2018-2023)
  • Table 69. Rest of Europe Latent TB Detection, by End users USD Million (2018-2023)
  • Table 70. Rest of Europe Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 71. Rest of Europe Latent TB Detection, by Test USD Million (2018-2023)
  • Table 72. MEA Latent TB Detection, by Country USD Million (2018-2023)
  • Table 73. MEA Latent TB Detection, by End users USD Million (2018-2023)
  • Table 74. MEA Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 75. MEA Latent TB Detection, by Test USD Million (2018-2023)
  • Table 76. Middle East Latent TB Detection, by End users USD Million (2018-2023)
  • Table 77. Middle East Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 78. Middle East Latent TB Detection, by Test USD Million (2018-2023)
  • Table 79. Africa Latent TB Detection, by End users USD Million (2018-2023)
  • Table 80. Africa Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 81. Africa Latent TB Detection, by Test USD Million (2018-2023)
  • Table 82. North America Latent TB Detection, by Country USD Million (2018-2023)
  • Table 83. North America Latent TB Detection, by End users USD Million (2018-2023)
  • Table 84. North America Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 85. North America Latent TB Detection, by Test USD Million (2018-2023)
  • Table 86. United States Latent TB Detection, by End users USD Million (2018-2023)
  • Table 87. United States Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 88. United States Latent TB Detection, by Test USD Million (2018-2023)
  • Table 89. Canada Latent TB Detection, by End users USD Million (2018-2023)
  • Table 90. Canada Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 91. Canada Latent TB Detection, by Test USD Million (2018-2023)
  • Table 92. Mexico Latent TB Detection, by End users USD Million (2018-2023)
  • Table 93. Mexico Latent TB Detection, by Drug Type USD Million (2018-2023)
  • Table 94. Mexico Latent TB Detection, by Test USD Million (2018-2023)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Latent TB Detection: by End users(USD Million)
  • Table 105. Latent TB Detection Hospitals , by Region USD Million (2025-2030)
  • Table 106. Latent TB Detection Diagnostic Centers , by Region USD Million (2025-2030)
  • Table 107. Latent TB Detection Laboratories , by Region USD Million (2025-2030)
  • Table 108. Latent TB Detection Others , by Region USD Million (2025-2030)
  • Table 109. Latent TB Detection: by Drug Type(USD Million)
  • Table 110. Latent TB Detection First Line anti-TB Drugs , by Region USD Million (2025-2030)
  • Table 111. Latent TB Detection Second Line anti- TB Drugs , by Region USD Million (2025-2030)
  • Table 112. Latent TB Detection: by Test(USD Million)
  • Table 113. Latent TB Detection TB skin test , by Region USD Million (2025-2030)
  • Table 114. Latent TB Detection TB blood tests , by Region USD Million (2025-2030)
  • Table 115. South America Latent TB Detection, by Country USD Million (2025-2030)
  • Table 116. South America Latent TB Detection, by End users USD Million (2025-2030)
  • Table 117. South America Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 118. South America Latent TB Detection, by Test USD Million (2025-2030)
  • Table 119. Brazil Latent TB Detection, by End users USD Million (2025-2030)
  • Table 120. Brazil Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 121. Brazil Latent TB Detection, by Test USD Million (2025-2030)
  • Table 122. Argentina Latent TB Detection, by End users USD Million (2025-2030)
  • Table 123. Argentina Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 124. Argentina Latent TB Detection, by Test USD Million (2025-2030)
  • Table 125. Rest of South America Latent TB Detection, by End users USD Million (2025-2030)
  • Table 126. Rest of South America Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 127. Rest of South America Latent TB Detection, by Test USD Million (2025-2030)
  • Table 128. Asia Pacific Latent TB Detection, by Country USD Million (2025-2030)
  • Table 129. Asia Pacific Latent TB Detection, by End users USD Million (2025-2030)
  • Table 130. Asia Pacific Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 131. Asia Pacific Latent TB Detection, by Test USD Million (2025-2030)
  • Table 132. China Latent TB Detection, by End users USD Million (2025-2030)
  • Table 133. China Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 134. China Latent TB Detection, by Test USD Million (2025-2030)
  • Table 135. Japan Latent TB Detection, by End users USD Million (2025-2030)
  • Table 136. Japan Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 137. Japan Latent TB Detection, by Test USD Million (2025-2030)
  • Table 138. India Latent TB Detection, by End users USD Million (2025-2030)
  • Table 139. India Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 140. India Latent TB Detection, by Test USD Million (2025-2030)
  • Table 141. South Korea Latent TB Detection, by End users USD Million (2025-2030)
  • Table 142. South Korea Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 143. South Korea Latent TB Detection, by Test USD Million (2025-2030)
  • Table 144. Taiwan Latent TB Detection, by End users USD Million (2025-2030)
  • Table 145. Taiwan Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 146. Taiwan Latent TB Detection, by Test USD Million (2025-2030)
  • Table 147. Australia Latent TB Detection, by End users USD Million (2025-2030)
  • Table 148. Australia Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 149. Australia Latent TB Detection, by Test USD Million (2025-2030)
  • Table 150. Rest of Asia-Pacific Latent TB Detection, by End users USD Million (2025-2030)
  • Table 151. Rest of Asia-Pacific Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 152. Rest of Asia-Pacific Latent TB Detection, by Test USD Million (2025-2030)
  • Table 153. Europe Latent TB Detection, by Country USD Million (2025-2030)
  • Table 154. Europe Latent TB Detection, by End users USD Million (2025-2030)
  • Table 155. Europe Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 156. Europe Latent TB Detection, by Test USD Million (2025-2030)
  • Table 157. Germany Latent TB Detection, by End users USD Million (2025-2030)
  • Table 158. Germany Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 159. Germany Latent TB Detection, by Test USD Million (2025-2030)
  • Table 160. France Latent TB Detection, by End users USD Million (2025-2030)
  • Table 161. France Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 162. France Latent TB Detection, by Test USD Million (2025-2030)
  • Table 163. Italy Latent TB Detection, by End users USD Million (2025-2030)
  • Table 164. Italy Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 165. Italy Latent TB Detection, by Test USD Million (2025-2030)
  • Table 166. United Kingdom Latent TB Detection, by End users USD Million (2025-2030)
  • Table 167. United Kingdom Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 168. United Kingdom Latent TB Detection, by Test USD Million (2025-2030)
  • Table 169. Netherlands Latent TB Detection, by End users USD Million (2025-2030)
  • Table 170. Netherlands Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 171. Netherlands Latent TB Detection, by Test USD Million (2025-2030)
  • Table 172. Rest of Europe Latent TB Detection, by End users USD Million (2025-2030)
  • Table 173. Rest of Europe Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 174. Rest of Europe Latent TB Detection, by Test USD Million (2025-2030)
  • Table 175. MEA Latent TB Detection, by Country USD Million (2025-2030)
  • Table 176. MEA Latent TB Detection, by End users USD Million (2025-2030)
  • Table 177. MEA Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 178. MEA Latent TB Detection, by Test USD Million (2025-2030)
  • Table 179. Middle East Latent TB Detection, by End users USD Million (2025-2030)
  • Table 180. Middle East Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 181. Middle East Latent TB Detection, by Test USD Million (2025-2030)
  • Table 182. Africa Latent TB Detection, by End users USD Million (2025-2030)
  • Table 183. Africa Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 184. Africa Latent TB Detection, by Test USD Million (2025-2030)
  • Table 185. North America Latent TB Detection, by Country USD Million (2025-2030)
  • Table 186. North America Latent TB Detection, by End users USD Million (2025-2030)
  • Table 187. North America Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 188. North America Latent TB Detection, by Test USD Million (2025-2030)
  • Table 189. United States Latent TB Detection, by End users USD Million (2025-2030)
  • Table 190. United States Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 191. United States Latent TB Detection, by Test USD Million (2025-2030)
  • Table 192. Canada Latent TB Detection, by End users USD Million (2025-2030)
  • Table 193. Canada Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 194. Canada Latent TB Detection, by Test USD Million (2025-2030)
  • Table 195. Mexico Latent TB Detection, by End users USD Million (2025-2030)
  • Table 196. Mexico Latent TB Detection, by Drug Type USD Million (2025-2030)
  • Table 197. Mexico Latent TB Detection, by Test USD Million (2025-2030)
  • Table 198. Research Programs/Design for This Report
  • Table 199. Key Data Information from Secondary Sources
  • Table 200. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Latent TB Detection: by End users USD Million (2018-2023)
  • Figure 5. Global Latent TB Detection: by Drug Type USD Million (2018-2023)
  • Figure 6. Global Latent TB Detection: by Test USD Million (2018-2023)
  • Figure 7. South America Latent TB Detection Share (%), by Country
  • Figure 8. Asia Pacific Latent TB Detection Share (%), by Country
  • Figure 9. Europe Latent TB Detection Share (%), by Country
  • Figure 10. MEA Latent TB Detection Share (%), by Country
  • Figure 11. North America Latent TB Detection Share (%), by Country
  • Figure 12. Global Latent TB Detection share by Players 2023 (%)
  • Figure 13. Global Latent TB Detection share by Players (Top 3) 2023(%)
  • Figure 14. Global Latent TB Detection share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. QIAGEN (Germany) Revenue, Net Income and Gross profit
  • Figure 17. QIAGEN (Germany) Revenue: by Geography 2023
  • Figure 18. BioMeriux S.A. (France) Revenue, Net Income and Gross profit
  • Figure 19. BioMeriux S.A. (France) Revenue: by Geography 2023
  • Figure 20. F. Hoffmann La-Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. F. Hoffmann La-Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 22. BD (United States) Revenue, Net Income and Gross profit
  • Figure 23. BD (United States) Revenue: by Geography 2023
  • Figure 24. ARKRAY, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 25. ARKRAY, Inc. (Japan) Revenue: by Geography 2023
  • Figure 26. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 27. Abbott (United States) Revenue: by Geography 2023
  • Figure 28. Serum Institute of India Pvt. Ltd (India) Revenue, Net Income and Gross profit
  • Figure 29. Serum Institute of India Pvt. Ltd (India) Revenue: by Geography 2023
  • Figure 30. Oxford Immunotec Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Oxford Immunotec Ltd (United Kingdom) Revenue: by Geography 2023
  • Figure 32. Lionex GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Lionex GmbH (Germany) Revenue: by Geography 2023
  • Figure 34. Global Latent TB Detection: by End users USD Million (2025-2030)
  • Figure 35. Global Latent TB Detection: by Drug Type USD Million (2025-2030)
  • Figure 36. Global Latent TB Detection: by Test USD Million (2025-2030)
  • Figure 37. South America Latent TB Detection Share (%), by Country
  • Figure 38. Asia Pacific Latent TB Detection Share (%), by Country
  • Figure 39. Europe Latent TB Detection Share (%), by Country
  • Figure 40. MEA Latent TB Detection Share (%), by Country
  • Figure 41. North America Latent TB Detection Share (%), by Country
List of companies from research coverage that are profiled in the study
  • QIAGEN (Germany)
  • BioMeriux S.A. (France)
  • F. Hoffmann La-Roche Ltd. (Switzerland)
  • BD (United States)
  • ARKRAY, Inc. (Japan)
  • Abbott (United States)
  • Serum Institute of India Pvt. Ltd (India)
  • Oxford Immunotec Ltd (United Kingdom)
  • Lionex GmbH (Germany)
Select User Access Type

Key Highlights of Report


Jan 2024 201 Pages 62 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Latent TB Detection Market Quantitative research analysis
Global Latent TB Detection Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as QIAGEN (Germany), BioMeriux S.A. (France), F. Hoffmann La-Roche Ltd. (Switzerland), BD (United States), ARKRAY, Inc. (Japan), Abbott (United States), Serum Institute of India Pvt. Ltd (India), Oxford Immunotec Ltd (United Kingdom) and Lionex GmbH (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Advancements Technology in Tuberculosis Diagnosis" is seen as one of major influencing trends for Latent TB Detection Market during projected period 2023-2030.
The Latent TB Detection market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Latent TB Detection Market Report?

Have a Query? Click Here

Other Related Reports

Ear Cancer Treatment Comprehensive Study by Type (Basal cell carcinoma, Melanoma, Adenoid cystic carcinoma, Adenocarcinoma, Squamous cell carcinoma), Application (To correct an irregularity of the ou...
$ 3750
MDMA-assisted Therapy Comprehensive Study by Type (DMT,, Peyote,, Ayahuasca,, Ibogaine., Others chemical compounds which include ketamine, MDMA, and LSD), Application (PTSD, Eating disorders, includi...
$ 3650
Transplant Rejection Treatment Comprehensive Study by Type (Hyperacute Transplant Rejection, Acute Transplant Rejection, Chronic Transplant Rejection), Drugs (Antirejection Medicines, Corticosteroids...
$ 3500
Non-ablative Lasers Comprehensive Study by Type (Non Fractional Lasers, Conventional Lasers), Application (Skin Pigmentation, Scars, Rhytides, Photo Aging), Technology (Radiofrequency Systems, Mid-I...
$ 3650
Posterior Cervical Spine System Comprehensive Study by Type (Anterior Cervical Fusion, Posterior Cervical Fusion), End-users (Hospitals, Ambulatory Surgical Centers, Specialty Orthopedic Clinics) Pla...
$ 3500
Hospital Acquired Disease Testing- Comprehensive Study by Type (Urinary Tract Infection, Pneumonia, Bloodstream, Surgical Site, Other), Drugs (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs),...
$ 3800